Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2002-05-10
2011-10-04
Wang, Shengjun (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S199000
Reexamination Certificate
active
08030314
ABSTRACT:
Use of 2H-benzimidazol-2-one, 1,3-dihydro-1-(2{4-[-(trifluoromethyl)phenyl]-1-piperazinyl}ethyl)- or a physiologically acceptable acid addition salt thereof, for the manufacture of a medicament for the treatment of extrapyramidal movement disorders. These extrapyramidal movement disorders may result from idopathic Parkinson's disease, from the adverse effects of the administration of anti-Parkinson drugs in idiopathic Parkinson's disease, from dyskinesias caused by idiopathic Parkinson's disease and/or long-term administration of anti-Parkinson drugs, from Parkinson-like or Parkinson-related syndromes of from Parkinsonoid symptoms. Another aspect of the present invention concerns a pharmaceutical composition comprising, as active ingredients-(I) 2H-benzimidazol-2-one, 1,3-dihydro-1-(2-{4-[3-(trifluoromethyl)phenyl]-1-piperazinyl}ethyl)-or a physiologically acceptable acid addition salt thereof, and (II) at least one anti-Parkinson drug, in combination with one or more pharmaceutically acceptable excipients.
REFERENCES:
patent: 5925627 (1999-07-01), Baker et al.
patent: 2 768 338 (1999-03-01), None
patent: WO 98/42344 (1998-10-01), None
Rang, H.P., Dale, M.M., Ritter, J.M., and P. Gardner, (1995). Pharmacology. Churchill Livingstone, New York. pp. 527-529.
Nakazato et al. Brain Research, 2002, vol. 930, pp. 134-142.
Trends in Neurosciences. Oct. 2000, vol. 23, Supplement 1, pp. S71-S77.
Evans, S.E. Gilbert, et al; “The effects of flibanserin on amphetamine withdrawal-induced hypolocomotion in rats”, Society for Neuroscience Abstracts, (1998), vol. 24, No. 1-2, pp. 2133.
Borsini F., et al.: Behavioral effects of flibanserin (BIMT 17), Pharmacology, Biochemistry and Behavior (Sep. 1999) 64 137-46.
Gupta, Y.K., et al.; “Therapeutic Potentials of 5-HT Receptor Modulators” Indian Journal of Pharmacology; vol. 26, No. 2,; (Jun. 1, 1994), pp. 94-107.
Borsini, F., et al.; “BIMT 17, a 5-HT2Areceptor antagonist and 5-HT1areceptor full agonist in rat cerebral cortex”; Naunyn-Schmiedebergs Archives of Pharmacology, (Sep. 1995), 352 (3); pp. 276-282.
Podhorna, J. et al.; “Flibanserin has anxiolytic effects without locomotor side effects in the infant rat ultrasonic vocalization model of anxiety”; British Journal of Pharmacology, (Jun. 2000) 130 (4) pp. 739-746.
Connolly Bove & Lodge & Hutz LLP
Jean-Louis Samira
Wang Shengjun
LandOfFree
Use of 2h-benzimidazol-2-one,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of 2h-benzimidazol-2-one,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of 2h-benzimidazol-2-one,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4265371